Nature Communications (Nov 2020)
Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19
- Kening Li,
- Bin Huang,
- Min Wu,
- Aifang Zhong,
- Lu Li,
- Yun Cai,
- Zhihua Wang,
- Lingxiang Wu,
- Mengyan Zhu,
- Jie Li,
- Ziyu Wang,
- Wei Wu,
- Wanlin Li,
- Bakwatanisa Bosco,
- Zhenhua Gan,
- Qinghua Qiao,
- Jian Wu,
- Qianghu Wang,
- Shukui Wang,
- Xinyi Xia
Affiliations
- Kening Li
- The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research
- Bin Huang
- Center for Global Health, School of Public Health, Nanjing Medical University
- Min Wu
- Center for Global Health, School of Public Health, Nanjing Medical University
- Aifang Zhong
- Medical Technical Support Division, the 904th Hospital
- Lu Li
- Center for Global Health, School of Public Health, Nanjing Medical University
- Yun Cai
- Center for Global Health, School of Public Health, Nanjing Medical University
- Zhihua Wang
- Department of Laboratory Medicine & Blood Transfusion, Wuhan Huoshenshan Hospital
- Lingxiang Wu
- Center for Global Health, School of Public Health, Nanjing Medical University
- Mengyan Zhu
- Center for Global Health, School of Public Health, Nanjing Medical University
- Jie Li
- Center for Global Health, School of Public Health, Nanjing Medical University
- Ziyu Wang
- Center for Global Health, School of Public Health, Nanjing Medical University
- Wei Wu
- Center for Global Health, School of Public Health, Nanjing Medical University
- Wanlin Li
- Center for Global Health, School of Public Health, Nanjing Medical University
- Bakwatanisa Bosco
- Center for Global Health, School of Public Health, Nanjing Medical University
- Zhenhua Gan
- Department of Medical Administration, Jinling Hospital, Nanjing University School of Medicine
- Qinghua Qiao
- Department of Laboratory Medicine & Blood Transfusion, Wuhan Huoshenshan Hospital
- Jian Wu
- COVID-19 Research Center, Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine
- Qianghu Wang
- The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research
- Shukui Wang
- Department of Laboratory Medicine, Nanjing First Hospital, Nanjing Medical University
- Xinyi Xia
- Department of Laboratory Medicine & Blood Transfusion, Wuhan Huoshenshan Hospital
- DOI
- https://doi.org/10.1038/s41467-020-19943-y
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 11
Abstract
Understanding antibody responses to Sars-CoV-2 proteins over time is complicated by many variables. Here the authors survey IgM and IgG antibodies against S protein, RBD and nucleoprotein in a large cohort of infected and recovering severe vs. moderate COVID-19 patients, comparing against clinical parameters and immunological readouts.
